VYNE Therapeutics (VYNE) FCF Margin (QoQ) (2017 - 2025)

VYNE Therapeutics (VYNE) FCF Margin (QoQ) (2017 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2025 -510,850.00
Mar 31, 2025 511,167.00
Dec 31, 2024 -380,911.00
Sep 30, 2024 -274,922.00
Jun 30, 2024 369,716.00
Mar 31, 2024 -122,179.00
Dec 31, 2023 -223,991.00
Sep 30, 2023 505,470.00
Jun 30, 2023 -409,600.00
Mar 31, 2023 1.11 Mn
Dec 31, 2022 -1.23 Mn
Sep 30, 2022 226,131.00
Jun 30, 2022 -144,969.00
Mar 31, 2022 -127,076.00
Dec 31, 2021 912,500.00
Sep 30, 2021 -758,148.00
Jun 30, 2021 -6,954.00
Mar 31, 2021 -468,926.00
Dec 31, 2020 13,102.00
Sep 30, 2020 -41,566.00